Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease

Core Insights - Genentech, a member of the Roche Group, announced that the Phase III MAJESTY study for Gazyva® (obinutuzumab) in adults with primary membranous nephropathy met its primary endpoint, demonstrating statistically significant and clinically meaningful results [1] Study Results - The study showed that significantly more patients achieved complete remission at two years (104 weeks) with Gazyva compared to tacrolimus [1] - Safety profile of Gazyva was consistent with previously characterized data [1]